George L Wright, Jr

Title: George L Wright, Jr: Innovator in Prostate Carcinoma Research

Introduction

George L Wright, Jr. is a notable inventor based in Norfolk, VA (US). He has made significant contributions to the field of medical research, particularly in the area of prostate carcinoma. With a total of 2 patents, his work has the potential to impact diagnosis and treatment options for this prevalent condition.

Latest Patents

Wright's latest patents focus on isolated nucleotide sequences that encode an antigen binding site of monoclonal antibodies. These antibodies specifically target prostate carcinoma while avoiding binding to normal prostate tissue or benign prostatic hyperplasia. One of the key embodiments of his work is a monoclonal antibody designated MAb PD41. Additionally, he has disclosed a new antigen known as prostate mucin antigen in an isolated, substantially pure form. His patents also include methods for utilizing the hybridoma cell lines, monoclonal antibodies, and antigens for the diagnosis, prophylaxis, and treatment of prostate carcinoma.

Career Highlights

Throughout his career, George L Wright, Jr. has been associated with esteemed institutions such as Eastern Virginia Medical School of the Medical College of Hampton Roads. His work in these organizations has allowed him to advance his research and contribute to the scientific community.

Collaborations

Due to space constraints, the details of his collaborations will not be included.

Conclusion

George L Wright, Jr. is a distinguished inventor whose work in prostate carcinoma research has led to valuable patents and advancements in medical science. His contributions continue to pave the way for improved diagnostic and therapeutic strategies.